C-KIT: Potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature

Clinical Genitourinary Cancer

Volumn 11, Issue 2, 2013, Pages 134-140

  Zhang, Hai Liang ^a   Zhu, Yao ^a   Qin, Xiao Jian ^a   Wang, Chao Fu ^a   Yao, Xu Dong ^a   Zhang, Shi Lin ^a   Dai, Bo ^a   Zhu, Yi Ping ^a   Shi, Guo Hai ^a   Ye, Ding Wei ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

c KIT; Sorafenib; Targeted therapy

Indexed keywords

CALCIUM; CHINESE DRUG; DOXORUBICIN; GEMCITABINE; LACTATE DEHYDROGENASE; PROTEIN P53; SORAFENIB; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CHINESE MEDICINE; CLINICAL ARTICLE; CLINICAL EVALUATION; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; ONCOGENE C KIT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84876996974     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.08.007     Document Type: Article

References (22)

1. A. Lopez-Beltran, M. Scarpelli, R. Montironi WHO classification of the renal tumors of the adults Eur Urol 2006 2004 798 805
2. G.M. Farrow, E.G. Harrison Jr., D.C. Utz Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. I Cancer 22 1968 545 550
3. A. Sella, C.J. Logothetis, J.Y. Ro, D.A. Swanson, M.L. Samuels Sarcomatoid renal cell carcinoma A treatable entity Cancer 60 1987 1313 1318
4. B. Delahunt Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies Pathology 31 1999 185 190
5. M. de Peralta-Venturina, H. Moch, M. Amin Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases Am J Surg Pathol 25 2001 275 284
6. J.C. Cheville, C.M. Lohse, H. Zincke Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome Am J Surg Pathol 28 2004 435 441
7. B.M. Mian, N. Bhadkamkar, J.W. Slaton Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma J Urol 167 2002 65 70
8. M.F. Dall'Oglio, M. Lieberknecht, V. Gouveia Sarcomatoid differentiation in renal cell carcinoma: prognostic implications Int Braz J Urol 31 2005 10 16
9. L. Li, S. Teichberg, J. Steckel Sarcomatoid renal cell carcinoma with divergent sarcomatoid growth patterns: a case report and review of the literature Arch Pathol Lab Med 129 2005 1057 1060
10. M. Staehler, N. Haseke, A. Roosen Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation Eur J Med Res 15 2010 287 291
11. M. Castillo, A. Petit, B. Mellado C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib J Urol 171 2004 2176 2180
12. A. Petit, M. Castillo, A. Gaspa Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma Histopathology 55 2009 230 232
13. J.L. Hornick, C.D. Fletcher Validating immunohistochemical staining for KIT (CD117) Am J Clin Pathol 119 2003 325 327
14. G. D'Amato, D.M. Steinert, J.C. McAuliffe Update on the biology and therapy of gastrointestinal stromal tumors Cancer Contr 12 2005 44 56
15. M. Miettinen, J. Lasota KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation Appl Immunohistochem Mol Morphol 13 2005 205 220
16. H. Zhang, D. Ye, X. Yao Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients J Cancer Res Clin Oncol 135 2009 249 253
17. R.J. Motzer, M. Mazumdar, J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
18. A.R. Golshayan, S. George, D.Y. Heng Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy J Clin Oncol 27 2009 235 241
19. C. Pena, C. Lathia, M. Shan Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III TARGET Clin Cancer Res 16 2010 4853 4863
20. S. Sengupta, J.C. Cheville, C.L. Corless Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma J Urol 175 2006 53 56
21. J. Vuky, C. Isacson, M. Fotoohi Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma Invest New Drugs 24 2006 85 88
22. B.N. Polite, A.A. Desai, B. Manchen Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial Clin Genitourin Cancer 4 2006 275 280